CORT Earnings Prediction
The chart below shows how CORT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CORT sees a -2.14% change in stock price 10 days leading up to the earnings, and a +2.63% change 10 days following the report. On the earnings day itself, the stock moves by +0.84%. This data can give you a slight idea of what to expect for the next quarter's release.
CORT Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
181.89M
34.33%
-0.36%
Gross Margin
98.37%
-0.24%
-0.06%
Operating Margin
13.89%
-40.62%
-45.59%
Net Margin
16.90%
-27.03%
-34.65%
EPS
0.26
-7.14%
-38.10%
No Data Available
CORT Earnings Analysis
Corcept Therapeutics Inc Corporation (CORT.O) Earnings Conference Call
Positive
Revenue Surge and Guidance: 2024 revenue increased by 40% to $675 million compared to the prior year, with a revenue guidance of $900 million to $950 million for 2025.
Net Income Increase: Net income for 2024 was $141 million, reflecting a 33% increase from the previous year.
Cash and Investments Increase: Cash and investments rose to $603 million at the end of 2024, up from $425 million at the end of 2023.
Korlym Market Demand Surge: Record number of new Korlym prescribers and patients receiving Korlym each quarter in 2024, indicating strong market demand.
NDA Submission for Relacorilant: The NDA for relacorilant was submitted based on compelling results from the GRACE GRADIENT long-term extension and Phase II studies.
Clinical Improvements with Relacorilant: Relacorilant demonstrated statistically significant improvements in hypertension, hyperglycemia, and other clinical measures in the GRACE study.
Long-term Patient Improvements: Patients in the long-term extension study of relacorilant exhibited additional clinically meaningful improvements over time.
Safety Profile of Relacorilant: Relacorilant has been well tolerated with no serious adverse events reported, distinguishing it from other available medications for Cushing's syndrome.
Hypercortisolism Prevalence Insights: The CATALYST study revealed that hypercortisolism is more prevalent than previously thought, with significant improvements in glucose control observed in patients treated with Korlym.
Ovarian Cancer Study Completion: Enrollment in the ROSELLA study for ovarian cancer is complete, with results expected soon, and the establishment of a stand-alone oncology division to expedite relacorilant's availability if results are positive.
ALS Trial Survival Improvement: Dazucorilant showed a statistically significant improvement in patient survival in an ALS trial, despite not meeting the primary endpoint.
Liver Fat Reduction Study: Miricorilant demonstrated a 30% reduction in liver fat in a Phase Ib study for MASH, with a Phase IIb study currently underway to further evaluate its efficacy.
Negative
Patent Lawsuit Outcome: The trial court ruled against Corcept in their patent lawsuit against Teva, which could impact their market position.
Patent Lawsuit Appeal Delay: The appeal process for the patent lawsuit against Teva is lengthy, with oral arguments not expected until May or later, delaying potential market advantages.
Litigation Impact on Earnings: Despite a strong revenue increase, the company faces ongoing litigation that could affect future earnings and market share.
Dazucorilant Trial Results: The Phase II trial of dazucorilant for ALS did not meet its primary endpoint, raising concerns about the efficacy of this treatment.
ALS Trial Investment Concerns: While there were some positive survival results in the ALS trial, the failure to meet primary endpoints may hinder future investment and development in this area.
Future Revenue Potential: The company is still in the early stages of several studies, meaning that significant revenue from new products may be a long way off.
CORT FAQs
How does CORT typically perform around its earnings report dates?
Is Corcept Therapeutics Inc (CORT) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CORT Earning Call Sentiment
Corcept Therapeutics, Inc. (CORT) Q4 2024 Earnings Call Transcript
CORT.O
2.11%Positive
The earnings call summary highlights strong financial performance, with a 40% revenue increase and a significant stock repurchase program. The NDA submission for relacorilant and the establishment of a standalone oncology division are positive developments. Despite legal and regulatory risks, the company's proactive strategy and increased revenue guidance suggest optimism. The Q&A section reveals confidence in regulatory outcomes and strategic adjustments, further supporting a positive outlook. Given the market cap, a positive sentiment is expected, leading to a likely stock price increase of 2% to 8%.
